{"id":{"repo_id":"greece","oai_identifier":"oai:10442/5366"},"canonical_url":"https://search.ndltd.org/etd/greece/oai:10442/5366","repository":{"repo_id":"greece","name":"Greek National Archive of PhD Theses","base_url":"https://phdtheses.ekt.gr/eadd_oai/request"},"display":{"title":"Η ΕΝΔΟΣΚΟΠΙΚΗ ΣΚΛΗΡΟΘΕΡΑΠΕΙΑ ΜΟΝΗ ΣΥΓΚΡΙΤΙΚΑ ΜΕ ΤΟΝ ΣΥΝΔΥΑΣΜΟ ΑΥΤΗΣ ΜΕ ΠΡΟΠΡΑΝΟΛΟΛΗ ΣΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΥΠΟΤΡΟΠΙΑΖΟΥΣΑΣ ΑΙΜΟΡΡΑΓΙΑΣ ΑΠΟ ΤΟ ΑΝΩΤΕΡΟ ΠΕΠΤΙΚΟ ΣΕ ΑΡΡΩΣΤΟΥΣ ΜΕ ΚΙΡΡΩΣΗ ΗΠΑΤΟΣ. ΠΡΟΟΠΤΙΚΗ ΜΕΛΕΤΗ","abstract":"THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE POSSIBLE VALUE OF LONG TERM ADMINISTRATION OF PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. SEVENTY ONE PATIENTS WITH LIVER CIRRHOSIS AND ACTIVE VARICEAL BLEEDING WHO SURVIVED THE INITIAL PHASE WERE STUDIED. AFTER INITIAL CONTROL OF HAEMORRHAGE 36 OF THE PATIENTS WERE RANDOMLY ASSIGNED TO SCLEROTHERAPY AND 35 TO THE COMBINATION OF SCLEROTHERAPY + PROPRANOLOL. SCLEROTHERAPY WAS CARRIED OUT WITH THE INTRAVARICEAL INJECTION OF 5% ETHANOLAMINE UNTIL OBLITERATION OF ESOPHAGEAL VARICES AT THE GASTRO-ESOPHAGEAL JUNCTION WAS ACHIEVED. VARICES WERE REINJECTED IF THEY RECURRED. PROPRANOLOL WAS GIVEN ORALLY TWICE A DAY UNTIL THE RECUMBENT HEART RATE WASREDUCED BY 25%. DURING A MEAN FOLLOW-UP PERIOD OF 25 AND 28.2 MONTHS FOR THE SCLEROTHERAPY AND THE SCLEROTHERAPY + PROPRANOLOL GROUPS 18 PATIENTS (32 BLEEDING EPISODES) AND 9 (17 EPISODES) RESPECTIVELY REBLED. THE LATTER GROUP HAD AMARGINALLY STATISTICALLY SIGNIFICANTLY LONGER FREEDOM FROM REBLEEDING (P=0.049). MOST OF THE BLEEDING EPISODES IN BOTH GROUPS (23/32 AND 14/17 RESPECTIVELY) WERE DUE TO RUPTURED ESOPHAGEAL VARICES. HOWEVER, PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY + PROPRANOLOL (P =0.032). THE DEATH RATE TENDED TO BE LOWER IN THE LATTER GROUP THAN IN THE ES BUT THIS DIFFERENCE WAS NOT SIGNIFICANT. (ABSTRACT TRUNCATED)","abstract_html":"THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE POSSIBLE VALUE OF LONG TERM ADMINISTRATION OF PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. SEVENTY ONE PATIENTS WITH LIVER CIRRHOSIS AND ACTIVE VARICEAL BLEEDING WHO SURVIVED THE INITIAL PHASE WERE STUDIED. AFTER INITIAL CONTROL OF HAEMORRHAGE 36 OF THE PATIENTS WERE RANDOMLY ASSIGNED TO SCLEROTHERAPY AND 35 TO THE COMBINATION OF SCLEROTHERAPY + PROPRANOLOL. SCLEROTHERAPY WAS CARRIED OUT WITH THE INTRAVARICEAL INJECTION OF 5% ETHANOLAMINE UNTIL OBLITERATION OF ESOPHAGEAL VARICES AT THE GASTRO-ESOPHAGEAL JUNCTION WAS ACHIEVED. VARICES WERE REINJECTED IF THEY RECURRED. PROPRANOLOL WAS GIVEN ORALLY TWICE A DAY UNTIL THE RECUMBENT HEART RATE WASREDUCED BY 25%. DURING A MEAN FOLLOW-UP PERIOD OF 25 AND 28.2 MONTHS FOR THE SCLEROTHERAPY AND THE SCLEROTHERAPY + PROPRANOLOL GROUPS 18 PATIENTS (32 BLEEDING EPISODES) AND 9 (17 EPISODES) RESPECTIVELY REBLED. THE LATTER GROUP HAD AMARGINALLY STATISTICALLY SIGNIFICANTLY LONGER FREEDOM FROM REBLEEDING (P=0.049). MOST OF THE BLEEDING EPISODES IN BOTH GROUPS (23/32 AND 14/17 RESPECTIVELY) WERE DUE TO RUPTURED ESOPHAGEAL VARICES. HOWEVER, PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY + PROPRANOLOL (P =0.032). THE DEATH RATE TENDED TO BE LOWER IN THE LATTER GROUP THAN IN THE ES BUT THIS DIFFERENCE WAS NOT SIGNIFICANT. (ABSTRACT TRUNCATED)","abstract_has_math":false,"creators":["Klonis, Chrisostomos","Κλώνης, Χρυσόστομος"],"institution":"National and Kapodistrian University of Athens","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1994,"date_issued":"1994","date_published":"1994","updated_at":"2026-11-18T20:24:22Z","subjects":["Κίρρωση ήπατος","Κιρσορραγία","Προπρανολόλη","Σκληροθεραπεία","ΥΠΟΤΡΟΠΙΑΖΟΥΣΑ ΑΙΜΟΡΡΑΓΙΑ","Cirrhosis","Propranolol","RECURRENT BLEEDING","Sclerotherapy","VERICEAL BLEEDING","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"languages":["gre"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/5366"],"render_values":[{"text":"10.12681/eadd/5366","href":"https://doi.org/10.12681/eadd/5366","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10442/hedi/5366","outbound_label":"Handle","outbound_source":"dc:identifier","record_url":"http://hdl.handle.net/10442/hedi/5366","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://phdtheses.ekt.gr/eadd_oai/request?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3A10442%2F5366","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Klonis, Chrisostomos","Κλώνης, Χρυσόστομος"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["1994"]},{"key":"dc:publisher","label":"Institution","values":["National and Kapodistrian University of Athens","Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)"]},{"key":"dc:type","label":"Dc Type","values":["PhD Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Κίρρωση ήπατος","Κιρσορραγία","Προπρανολόλη","Σκληροθεραπεία","ΥΠΟΤΡΟΠΙΑΖΟΥΣΑ ΑΙΜΟΡΡΑΓΙΑ","Cirrhosis","Propranolol","RECURRENT BLEEDING","Sclerotherapy","VERICEAL BLEEDING","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["gre"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/5366","http://hdl.handle.net/10442/hedi/5366"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE POSSIBLE VALUE OF LONG TERM ADMINISTRATION OF PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. SEVENTY ONE PATIENTS WITH LIVER CIRRHOSIS AND ACTIVE VARICEAL BLEEDING WHO SURVIVED THE INITIAL PHASE WERE STUDIED. AFTER INITIAL CONTROL OF HAEMORRHAGE 36 OF THE PATIENTS WERE RANDOMLY ASSIGNED TO SCLEROTHERAPY AND 35 TO THE COMBINATION OF SCLEROTHERAPY + PROPRANOLOL. SCLEROTHERAPY WAS CARRIED OUT WITH THE INTRAVARICEAL INJECTION OF 5% ETHANOLAMINE UNTIL OBLITERATION OF ESOPHAGEAL VARICES AT THE GASTRO-ESOPHAGEAL JUNCTION WAS ACHIEVED. VARICES WERE REINJECTED IF THEY RECURRED. PROPRANOLOL WAS GIVEN ORALLY TWICE A DAY UNTIL THE RECUMBENT HEART RATE WASREDUCED BY 25%. DURING A MEAN FOLLOW-UP PERIOD OF 25 AND 28.2 MONTHS FOR THE SCLEROTHERAPY AND THE SCLEROTHERAPY + PROPRANOLOL GROUPS 18 PATIENTS (32 BLEEDING EPISODES) AND 9 (17 EPISODES) RESPECTIVELY REBLED. THE LATTER GROUP HAD AMARGINALLY STATISTICALLY SIGNIFICANTLY LONGER FREEDOM FROM REBLEEDING (P=0.049). MOST OF THE BLEEDING EPISODES IN BOTH GROUPS (23/32 AND 14/17 RESPECTIVELY) WERE DUE TO RUPTURED ESOPHAGEAL VARICES. HOWEVER, PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY + PROPRANOLOL (P =0.032). THE DEATH RATE TENDED TO BE LOWER IN THE LATTER GROUP THAN IN THE ES BUT THIS DIFFERENCE WAS NOT SIGNIFICANT. (ABSTRACT TRUNCATED)","ΣΚΟΠΟΣ ΤΗΣ ΜΕΛΕΤΗΣ ΗΤΑΝ ΝΑ ΕΡΕΥΝΗΘΕΙ ΚΑΤΑ ΠΟΣΟ Η ΤΑΥΤΟΧΡΟΝΗ ΧΟΡΗΓΗΣΗ ΠΡΟΠΡΑΝΟΛΟΛΗΣ ΣΕ ΚΙΡΡΩΤΙΚΟΥΣ ΠΟΥ ΥΠΟΒΑΛΛΟΝΤΑΙ ΣΕ ΣΚΛΗΡΟΘΕΡΑΠΕΙΑ (ES) ΒΟΗΘΑ ΣΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΥΠΟΤΡΟΠΗΣ ΑΙΜΟΡΡΑΓΙΑΣ ΑΠΟ ΤΟ ΑΝΩΤΕΡΟ ΠΕΠΤΙΚΟ. ΜΕΛΕΤΗΘΗΚΑΝ 71 ΑΣΘΕΝΕΙΣ ΜΕ ΚΙΡΡΩΣΗ ΗΠΑΤΟΣ (15 ΑΛΚΟΟΛΙΚΗΣ, 56 ΜΗ ΑΛΚΟΟΛΙΚΗΣ ΑΙΤΙΟΛΟΓΙΑΣ) ΠΟΥ ΑΠΟΔΕΔΕΙΓΜΕΝΑΠΑΡΟΥΣΙΑΖΑΝ ΕΝΕΡΓΟ ΑΙΜΟΡΡΑΓΙΑ ΑΠΟ ΚΙΡΣΟΥΣ ΣΤΗΝ ΕΠΕΙΓΟΥΣΑ ΕΝΔΟΣΚΟΠΗΣΗ. ΜΕΤΑ ΤΟΝ ΑΡΧΙΚΟ ΕΛΕΓΧΟ ΤΗΣ ΑΙΜΟΡΡΑΓΙΑΣ 36 ΑΠΟ ΤΟΥΣ ΑΣΘΕΝΕΙΣ ΧΩΡΙΣΤΗΚΑΝ ΤΥΧΑΙΑ ΣΤΗΝ ΟΜΑΔΑ ΤΗΣ ES (ΣΤΑΔΙΟΠΟΙΗΣΗ ΚΑΤΑ CHILD 11A, 18B, 7C) ΚΑΙ 35 (12A, 15B, 8C) ΣΤΗΝ ΟΜΑΔΑ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ ES ΚΑΙ ΠΡΟΠΡΑΝΟΛΟΛΗΣ. Η ES ΓΙΝΟΤΑΝ ΜΕ ΕΝΔΟΚΙΡΣΙΚΗ ΕΓΧΥΣΗΕΘΑΝΟΛΑΜΙΝΗΣ 5% ΜΕ ΕΥΚΑΜΠΤΟ ΕΝΔΟΣΚΟΠΙΟ. Η ΣΥΝΕΔΡΙΑ ΕΠΑΝΑΛΑΜΒΑΝΟΤΑΝ ΚΑΘΕ ΕΒΔΟΜΑΔΑ ΜΕΧΡΙΣ ΕΞΑΛΕΙΨΕΩΣ ΤΩΝ ΚΙΡΣΩΝ ΣΤΗΝ ΓΑΣΤΡΟΟΙΣΟΦΑΓΙΚΗ ΣΥΜΒΟΛΗ. Η ΠΡΟΠΡΑΝΟΛΟΛΗ ΧΟΡΗΓΕΙΤΟ ΑΠΟ ΤΟ ΣΤΟΜΑ, ΔΥΟ ΦΟΡΕΣ ΤΗΝ ΗΜΕΡΑ ΚΑΙ Η ΔΟΣΗ ΠΡΟΣΑΡΜΟΖΟΤΑΝ ΜΕΣΑ ΣΕ2-4 ΜΕΡΕΣ ΕΤΣΙ ΩΣΤΕ ΝΑ ΕΛΑΤΤΩΘΕΙ Ο ΚΑΡΔΙΑΚΟΣ ΡΥΘΜΟΣ ΚΑΤΑ 25% ΠΕΡΙΠΟΥ ΜΕ ΤΟΝ ΑΣΘΕΝΗ ΚΑΤΑΚΕΚΛΙΜΕΝΟ ΚΑΙ ΣΕ ΦΑΣΗ ΗΡΕΜΙΑΣ. ΟΙ ΔΥΟ ΟΜΑΔΕΣ ΗΤΑΝ ΣΥΓΚΡΙΣΙΜΕΣ ΟΣΟΝ ΑΦΟΡΑ ΤΟ ΦΥΛΟ ΚΑΙ ΤΗΝ ΗΛΙΚΙΑ. Ο ΜΕΣΟΣ ΧΡΟΝΟΣ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΗΤΑΝ ΟΜΟΙΟΣ ΚΑΙ ΣΤΙΣ ΔΥΟ ΟΜΑΔΕΣ (25 ΜΗΝΕΣ +- 1,2 SE ΚΑΙ 28,2 +- 1,1 ΑΝΤΙΣΤΟΙΧΑ). ΚΑΤΑ ΤΗ ΔΙΑΡΚΕΙΑΑΥΤΗΣ ΤΗΣ ΠΕΡΙΟΔΟΥ ΕΝΑΣ ΣΗΜΑΝΤΙΚΑ (P < 0.05) ΜΕΓΑΛΥΤΕΡΟΣ ΑΡΙΘΜΟΣ ΕΠΕΙΣΟΔΙΩΝ ΑΙΜΟΡΡΑΓΙΑΣ (32) ΣΥΝΕΒΗΚΕ ΣΤΗΝ ES ΟΜΑΔΑ ΣΕ ΣΥΓΚΡΙΣΗ ΜΕ ΤΗΝ ΟΜΑΔΑ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ (17). ΣΤΑ ΠΛΕΙΣΤΑ ΤΩΝ ΕΠΕΙΣΟΔΙΩΝ ΑΥΤΩΝ ΚΑΙ ΣΤΙΣ ΔΥΟ ΟΜΑΔΕΣ (23/32 ΚΑΙ 14/17 ΑΝΤΙΣΤΟΙΧΑ) Η ΑΙΜΟΡΡΑΓΙΑ ΟΦΕΙΛΟΤΑΝ ΣΕ ΡΗΞΗ ΟΙΣΟΦΑΓΙΚΩΝ ΚΙΡΣΩΝ. (ΠΕΡΙΚΟΠΗ ΠΕΡΙΛΗΨΗΣ)"]},{"key":"dc:title","label":"Title","values":["Η ΕΝΔΟΣΚΟΠΙΚΗ ΣΚΛΗΡΟΘΕΡΑΠΕΙΑ ΜΟΝΗ ΣΥΓΚΡΙΤΙΚΑ ΜΕ ΤΟΝ ΣΥΝΔΥΑΣΜΟ ΑΥΤΗΣ ΜΕ ΠΡΟΠΡΑΝΟΛΟΛΗ ΣΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΥΠΟΤΡΟΠΙΑΖΟΥΣΑΣ ΑΙΜΟΡΡΑΓΙΑΣ ΑΠΟ ΤΟ ΑΝΩΤΕΡΟ ΠΕΠΤΙΚΟ ΣΕ ΑΡΡΩΣΤΟΥΣ ΜΕ ΚΙΡΡΩΣΗ ΗΠΑΤΟΣ. ΠΡΟΟΠΤΙΚΗ ΜΕΛΕΤΗ","PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. A RANDOMIZED CONTROLLED STUDY"]}]}],"canonical_facts":{"dc:creator":["Klonis, Chrisostomos","Κλώνης, Χρυσόστομος"],"dc:date":["1994"],"dc:description":["THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE POSSIBLE VALUE OF LONG TERM ADMINISTRATION OF PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. SEVENTY ONE PATIENTS WITH LIVER CIRRHOSIS AND ACTIVE VARICEAL BLEEDING WHO SURVIVED THE INITIAL PHASE WERE STUDIED. AFTER INITIAL CONTROL OF HAEMORRHAGE 36 OF THE PATIENTS WERE RANDOMLY ASSIGNED TO SCLEROTHERAPY AND 35 TO THE COMBINATION OF SCLEROTHERAPY + PROPRANOLOL. SCLEROTHERAPY WAS CARRIED OUT WITH THE INTRAVARICEAL INJECTION OF 5% ETHANOLAMINE UNTIL OBLITERATION OF ESOPHAGEAL VARICES AT THE GASTRO-ESOPHAGEAL JUNCTION WAS ACHIEVED. VARICES WERE REINJECTED IF THEY RECURRED. PROPRANOLOL WAS GIVEN ORALLY TWICE A DAY UNTIL THE RECUMBENT HEART RATE WASREDUCED BY 25%. DURING A MEAN FOLLOW-UP PERIOD OF 25 AND 28.2 MONTHS FOR THE SCLEROTHERAPY AND THE SCLEROTHERAPY + PROPRANOLOL GROUPS 18 PATIENTS (32 BLEEDING EPISODES) AND 9 (17 EPISODES) RESPECTIVELY REBLED. THE LATTER GROUP HAD AMARGINALLY STATISTICALLY SIGNIFICANTLY LONGER FREEDOM FROM REBLEEDING (P=0.049). MOST OF THE BLEEDING EPISODES IN BOTH GROUPS (23/32 AND 14/17 RESPECTIVELY) WERE DUE TO RUPTURED ESOPHAGEAL VARICES. HOWEVER, PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY ONLY WERE MORE PRONE TO BLEED FROM GASTRIC SOURCES THAN PATIENTS TREATED WITH SCLEROTHERAPY + PROPRANOLOL (P =0.032). THE DEATH RATE TENDED TO BE LOWER IN THE LATTER GROUP THAN IN THE ES BUT THIS DIFFERENCE WAS NOT SIGNIFICANT. (ABSTRACT TRUNCATED)","ΣΚΟΠΟΣ ΤΗΣ ΜΕΛΕΤΗΣ ΗΤΑΝ ΝΑ ΕΡΕΥΝΗΘΕΙ ΚΑΤΑ ΠΟΣΟ Η ΤΑΥΤΟΧΡΟΝΗ ΧΟΡΗΓΗΣΗ ΠΡΟΠΡΑΝΟΛΟΛΗΣ ΣΕ ΚΙΡΡΩΤΙΚΟΥΣ ΠΟΥ ΥΠΟΒΑΛΛΟΝΤΑΙ ΣΕ ΣΚΛΗΡΟΘΕΡΑΠΕΙΑ (ES) ΒΟΗΘΑ ΣΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΥΠΟΤΡΟΠΗΣ ΑΙΜΟΡΡΑΓΙΑΣ ΑΠΟ ΤΟ ΑΝΩΤΕΡΟ ΠΕΠΤΙΚΟ. ΜΕΛΕΤΗΘΗΚΑΝ 71 ΑΣΘΕΝΕΙΣ ΜΕ ΚΙΡΡΩΣΗ ΗΠΑΤΟΣ (15 ΑΛΚΟΟΛΙΚΗΣ, 56 ΜΗ ΑΛΚΟΟΛΙΚΗΣ ΑΙΤΙΟΛΟΓΙΑΣ) ΠΟΥ ΑΠΟΔΕΔΕΙΓΜΕΝΑΠΑΡΟΥΣΙΑΖΑΝ ΕΝΕΡΓΟ ΑΙΜΟΡΡΑΓΙΑ ΑΠΟ ΚΙΡΣΟΥΣ ΣΤΗΝ ΕΠΕΙΓΟΥΣΑ ΕΝΔΟΣΚΟΠΗΣΗ. ΜΕΤΑ ΤΟΝ ΑΡΧΙΚΟ ΕΛΕΓΧΟ ΤΗΣ ΑΙΜΟΡΡΑΓΙΑΣ 36 ΑΠΟ ΤΟΥΣ ΑΣΘΕΝΕΙΣ ΧΩΡΙΣΤΗΚΑΝ ΤΥΧΑΙΑ ΣΤΗΝ ΟΜΑΔΑ ΤΗΣ ES (ΣΤΑΔΙΟΠΟΙΗΣΗ ΚΑΤΑ CHILD 11A, 18B, 7C) ΚΑΙ 35 (12A, 15B, 8C) ΣΤΗΝ ΟΜΑΔΑ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ ES ΚΑΙ ΠΡΟΠΡΑΝΟΛΟΛΗΣ. Η ES ΓΙΝΟΤΑΝ ΜΕ ΕΝΔΟΚΙΡΣΙΚΗ ΕΓΧΥΣΗΕΘΑΝΟΛΑΜΙΝΗΣ 5% ΜΕ ΕΥΚΑΜΠΤΟ ΕΝΔΟΣΚΟΠΙΟ. Η ΣΥΝΕΔΡΙΑ ΕΠΑΝΑΛΑΜΒΑΝΟΤΑΝ ΚΑΘΕ ΕΒΔΟΜΑΔΑ ΜΕΧΡΙΣ ΕΞΑΛΕΙΨΕΩΣ ΤΩΝ ΚΙΡΣΩΝ ΣΤΗΝ ΓΑΣΤΡΟΟΙΣΟΦΑΓΙΚΗ ΣΥΜΒΟΛΗ. Η ΠΡΟΠΡΑΝΟΛΟΛΗ ΧΟΡΗΓΕΙΤΟ ΑΠΟ ΤΟ ΣΤΟΜΑ, ΔΥΟ ΦΟΡΕΣ ΤΗΝ ΗΜΕΡΑ ΚΑΙ Η ΔΟΣΗ ΠΡΟΣΑΡΜΟΖΟΤΑΝ ΜΕΣΑ ΣΕ2-4 ΜΕΡΕΣ ΕΤΣΙ ΩΣΤΕ ΝΑ ΕΛΑΤΤΩΘΕΙ Ο ΚΑΡΔΙΑΚΟΣ ΡΥΘΜΟΣ ΚΑΤΑ 25% ΠΕΡΙΠΟΥ ΜΕ ΤΟΝ ΑΣΘΕΝΗ ΚΑΤΑΚΕΚΛΙΜΕΝΟ ΚΑΙ ΣΕ ΦΑΣΗ ΗΡΕΜΙΑΣ. ΟΙ ΔΥΟ ΟΜΑΔΕΣ ΗΤΑΝ ΣΥΓΚΡΙΣΙΜΕΣ ΟΣΟΝ ΑΦΟΡΑ ΤΟ ΦΥΛΟ ΚΑΙ ΤΗΝ ΗΛΙΚΙΑ. Ο ΜΕΣΟΣ ΧΡΟΝΟΣ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΗΤΑΝ ΟΜΟΙΟΣ ΚΑΙ ΣΤΙΣ ΔΥΟ ΟΜΑΔΕΣ (25 ΜΗΝΕΣ +- 1,2 SE ΚΑΙ 28,2 +- 1,1 ΑΝΤΙΣΤΟΙΧΑ). ΚΑΤΑ ΤΗ ΔΙΑΡΚΕΙΑΑΥΤΗΣ ΤΗΣ ΠΕΡΙΟΔΟΥ ΕΝΑΣ ΣΗΜΑΝΤΙΚΑ (P < 0.05) ΜΕΓΑΛΥΤΕΡΟΣ ΑΡΙΘΜΟΣ ΕΠΕΙΣΟΔΙΩΝ ΑΙΜΟΡΡΑΓΙΑΣ (32) ΣΥΝΕΒΗΚΕ ΣΤΗΝ ES ΟΜΑΔΑ ΣΕ ΣΥΓΚΡΙΣΗ ΜΕ ΤΗΝ ΟΜΑΔΑ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ (17). ΣΤΑ ΠΛΕΙΣΤΑ ΤΩΝ ΕΠΕΙΣΟΔΙΩΝ ΑΥΤΩΝ ΚΑΙ ΣΤΙΣ ΔΥΟ ΟΜΑΔΕΣ (23/32 ΚΑΙ 14/17 ΑΝΤΙΣΤΟΙΧΑ) Η ΑΙΜΟΡΡΑΓΙΑ ΟΦΕΙΛΟΤΑΝ ΣΕ ΡΗΞΗ ΟΙΣΟΦΑΓΙΚΩΝ ΚΙΡΣΩΝ. (ΠΕΡΙΚΟΠΗ ΠΕΡΙΛΗΨΗΣ)"],"dc:identifier":["10.12681/eadd/5366","http://hdl.handle.net/10442/hedi/5366"],"dc:language":["gre"],"dc:publisher":["National and Kapodistrian University of Athens","Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)"],"dc:subject":["Κίρρωση ήπατος","Κιρσορραγία","Προπρανολόλη","Σκληροθεραπεία","ΥΠΟΤΡΟΠΙΑΖΟΥΣΑ ΑΙΜΟΡΡΑΓΙΑ","Cirrhosis","Propranolol","RECURRENT BLEEDING","Sclerotherapy","VERICEAL BLEEDING","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"dc:title":["Η ΕΝΔΟΣΚΟΠΙΚΗ ΣΚΛΗΡΟΘΕΡΑΠΕΙΑ ΜΟΝΗ ΣΥΓΚΡΙΤΙΚΑ ΜΕ ΤΟΝ ΣΥΝΔΥΑΣΜΟ ΑΥΤΗΣ ΜΕ ΠΡΟΠΡΑΝΟΛΟΛΗ ΣΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΥΠΟΤΡΟΠΙΑΖΟΥΣΑΣ ΑΙΜΟΡΡΑΓΙΑΣ ΑΠΟ ΤΟ ΑΝΩΤΕΡΟ ΠΕΠΤΙΚΟ ΣΕ ΑΡΡΩΣΤΟΥΣ ΜΕ ΚΙΡΡΩΣΗ ΗΠΑΤΟΣ. ΠΡΟΟΠΤΙΚΗ ΜΕΛΕΤΗ","PROPRANOLOL IN THE PREVENTION OF RECURRENT UPPER GASTROINTESTINAL BLEEDING IN CIRRHOTICS UNDERGOING ENDOSCOPIC SCLEROTHERAPY. A RANDOMIZED CONTROLLED STUDY"],"dc:type":["PhD Thesis"]},"updated_at":"2026-11-18T20:24:22Z"}